Combination Therapy for Insulin Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type 2 diabetes and insulin resistance, particularly HISS-dependent insulin resistance, are inadequate as they often result in postprandial hyperglycemia, hyperlipidemia, and significant side effects such as hypoglycemia and weight gain, with limited effective combination therapies available.
Innovation Solution
A pharmaceutical composition comprising a modulator of hepatic parasympathetic tone, such as a cholinergic agonist or nitric oxide donor, combined with a diabetes drug like N-acetylcysteine or α-lipoic acid, to enhance insulin sensitivity and reduce adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional diabetes drugs are used to treat insulin resistance, then glycemic control is achieved, but hypoglycemia and weight gain occur as side effects
Solution Approach 1:
The patent combines a modulator of hepatic parasympathetic tone with a diabetes drug to create a combination therapy that achieves glycemic control while reducing the harmful side effects of hypoglycemia and weight gain that occur with conventional monotherapy
Solution Approach 2:
The modulator of hepatic parasympathetic tone acts as an intermediary substance that enhances the therapeutic effect of the diabetes drug while mitigating its adverse effects, allowing for lower doses of the diabetes drug to be used
2Reliability
If high doses of diabetes drugs are administered to achieve glycemic control, then insulin resistance is treated, but the incidence of side effects increases
Solution Approach 1:
The patent changes the dosage parameter of the diabetes drug by using lower doses in combination with a modulator of hepatic parasympathetic tone, thereby maintaining glycemic control while reducing the incidence of side effects that occur with high-dose monotherapy
3Reliability
If existing combination therapies are used for insulin resistance, then treatment effectiveness is improved, but the complexity of therapy increases
Solution Approach 1:
The patent merges a modulator of hepatic parasympathetic tone with a diabetes drug into a coordinated treatment regimen that improves treatment effectiveness for insulin resistance while maintaining manageable therapy complexity through rational drug selection and dosing
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy significantly improves insulin sensitivity, reduces the incidence of side effects like hypoglycemia and weight gain, and requires lower doses of diabetes drugs to achieve glycemic control, effectively addressing insulin resistance and related metabolic disorders.
Implementation Method 1
hepatic parasympathetic nerves provide a permissive signal to the liver that regulates the ability of insulin to stimulate the release of a hormone, HISS
Implementation Method 2
blockade of hepatic nitric oxide production
Implementation Method 3
insulin to stimulate the release of a hormone, HISS, from the liver. HISS selectively stimulates glucose uptake and storage as glycogen in skeletal muscle
Data Source
AI summary
The present invention provides pharmaceutical compositions comprising: (a) a modulator of hepatic parasympathetic tone, (b) at least one diabetes drug, and (c) a pharmaceutically acceptable carrier. The present invention includes methods for the treatment and/or prevention of insulin resistance, type 2 diabetes, impaired glucose intolerance, and other associated disorders with pharmaceutical compositions described herein. The invention also provides for a kit comprising a pharmaceutical composition and instructions for its use.